Delinia

In January 2017 Celgene (NASDAQ: CELG) agreed to acquire Delinia to continue development of its novel biologic therapeutics to treat autoimmune disease, including lead program DEL-106. 

Headquarters Cambridge, MA and San Francisco, CA
Website deliniabio.com
Pipeline Preclinical